Document is current
Any future updates will be listed below
-
Authors
Benavent, D.
Fernández-Luque, L.
Sanz-Jardón, M.
Bilionis, I.
Novella-Navarro, M.
Navarro-Compán, V.
González-Sanz, P. L.
Calvo, E.
Lojo, L.
Balsa, A.
Plasencia-Rodríguez, Ch
- License Information
-
More Information
Article History
Received: 13 March 2023
Accepted: 19 September 2023
First Online: 25 September 2023
Declarations
:
: The ethics committee of the University Hospital La Paz approved the study (PI-4519), and ratified by Hospital Infanta Leonor. Informed consent was obtained from all subjects.
: Not applicable.
: Disclosure of interest: Diego Benavent Speakers bureau: Jannsen, Roche, Grant/research support from: Novartis, Abbvie. Luis Fernández-Luque Employee of: AdheraHealth Inc. Ioannis Bilionis is an employee of AdheraHealth Inc. Marta Novella Navarro reports grants from UCB, Lilly and Janssen. Victoria Navarro-Compán. Speakers bureau: AbbVie, Eli Lilly, Janssen, MSD, Novartis, Pfizer, UCB Pharma, Consultant of: AbbVie, Eli Lilly, MSD, Novartis, Pfizer, UCB Pharma, Grant/research support from: AbbVie and Novartis. María Sanz: None declared. Enrique Calvo Aranda Speakers bureau: Abbvie. Leticia Lojo: None declared. Pedro Luis González Sanz is an employee of AdheraHealth Inc. Alejandro Balsa Speakers bureau: Pfizer, Abbvie, Lilly, Galapagos, BMS, Sandoz, Nordic Pharma, Gebro, Roche, Sanofi, UCB, Consultant of: Pfizer, Abbvie, Lilly, Galapagos, BMS, Nordic Pharma, Sanofi, UCB, Grant/research support from: Pfizer, Abbvie, BMS, Nordic Pharma, Gebro, Roche, UCB. Chamaida Plasencia Speakers bureau: Pfizer, Abbvie, Lilly, Sandoz, Sanofi, Biogen, Roche, Novartis, Grant/research support from: Pfizer and Abbvie. The rest of the authors declare no conflicts of interest.
